Scholarlink

<p>The Lurasidone Hydrochloride (LH) phospholipid complex was formulated in this study to improve its solubility, stability, bioavailability, and controlled release properties. The phospholipid complex of LH was produced using a solvent evaporation approach with a 33 complete factorial design, and its physicochemical and functional properties were evaluated. Differential scanning calorimetry (DSC), scanning electron microscopy (SEM), entrapment efficiency, powder X-ray diffraction (PXRD), nuclear magnetic resonance (NMR), particle size and zeta potential analysis, and Fourier transform infrared spectroscopy (FTIR) were employed to confirm the presence of LH in the phospholipid matrix. In vitro dissolution experiments using biorelevant media conditions (FaSSGF followed by FaSSIF-V2) indicated an excellent gastro protective response due to &lt; 13% drug release during the first 2&#xa0;h and then controlled release up to 95.8 ± 3.7% after 24&#xa0;h. Such a pH-dependent drug release pattern helped with enhanced drug delivery through lymphatic channels. Results from pharmacokinetic studies conducted in rats indicated an enhancement in bioavailability with 2.2-folds increase in AUC₀₋₂₄ and increased mean residence time in the case of LH-PLC compared to LH suspension, confirming enhanced oral bioavailability. The results suggest successful integration of LH into the phospholipid matrix, potentially enhancing solubility, bioavailability, and therapeutic efficacy of LH-PLC against schizophrenia, presenting a promising approach for more effective schizophrenia treatment.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Phospholipid-Based Lurasidone Hydrochloride Complex: Formulation, Characterization, Biorelevant Dissolution with IVIVC Correlation, and Enhanced Bioavailability

  • 期刊论文

  • 发表日期：

    2026年7月1日

查看全文
  • Suprit D. Saoji,
  • Anjali Dighe,
  • Dilisha Patil,
  • Yash Pawar,
  • Mohammad Adnan Raza,
  • Nilesh Rarokar,
  • Poorna Chander Marri,
  • Rajan Kalamkar

摘要

The Lurasidone Hydrochloride (LH) phospholipid complex was formulated in this study to improve its solubility, stability, bioavailability, and controlled release properties. The phospholipid complex of LH was produced using a solvent evaporation approach with a 33 complete factorial design, and its physicochemical and functional properties were evaluated. Differential scanning calorimetry (DSC), scanning electron microscopy (SEM), entrapment efficiency, powder X-ray diffraction (PXRD), nuclear magnetic resonance (NMR), particle size and zeta potential analysis, and Fourier transform infrared spectroscopy (FTIR) were employed to confirm the presence of LH in the phospholipid matrix. In vitro dissolution experiments using biorelevant media conditions (FaSSGF followed by FaSSIF-V2) indicated an excellent gastro protective response due to < 13% drug release during the first 2 h and then controlled release up to 95.8 ± 3.7% after 24 h. Such a pH-dependent drug release pattern helped with enhanced drug delivery through lymphatic channels. Results from pharmacokinetic studies conducted in rats indicated an enhancement in bioavailability with 2.2-folds increase in AUC₀₋₂₄ and increased mean residence time in the case of LH-PLC compared to LH suspension, confirming enhanced oral bioavailability. The results suggest successful integration of LH into the phospholipid matrix, potentially enhancing solubility, bioavailability, and therapeutic efficacy of LH-PLC against schizophrenia, presenting a promising approach for more effective schizophrenia treatment.

Graphical Abstract